Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a cheap blood thinner cut stroke risk in africa?

NCT ID NCT06919835

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug cilostazol can prevent recurrent strokes and heart problems in 1100 recent stroke survivors in Ghana. Participants take either cilostazol or a placebo twice daily for 24 months. The goal is to see if this affordable drug, already used in Asia, can reduce major cardiovascular events in a high-risk African population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cilostazol (a blood-thinning drug that helps prevent blood clots)
What this could lead to
If it works, this could provide an affordable and effective way to prevent recurrent strokes in low-resource settings like sub-Saharan Africa.
What could go wrong
This trial is still recruiting and results are not yet available. Previous promising data came mainly from Asian populations, so it may not work as well in Africans. Side effects like bleeding are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Above the age of 30 years; male or female (sex is a biological variable of interest) 2. Ischemic stroke or high-risk TIA (ABCD2 score \>= 6) diagnosis no greater than six months before enrollment. Ischemic strokes including lacunar, large vessel atherosclerotic, embolic stroke of undetermined source subtypes are eligible (Ischemic stroke or TIA should be confirmed by either with a cranial CT or MRI within 10 days of symptom onset) 3. Aspirin or clopidogrel monotherapy 4. Subjects with stroke may present with two or more of the following additional conditions: age ≥65 years, documented diabetes mellitus or previous treatment with oral hypoglycemic or insulin; documented hypertension \>140/90mmHg or previous treatment with anti-hypertensive medications; Mild to moderate renal dysfunction (eGFR 60-30ml/min/1.73m2); Prior myocardial infarction 5. Legally competent to sign informed consent or have a LARs who is able to provide consent for them 6. In the opinion of the treating physician, patient is medically stable, capable of participating in a randomized trial, and willing and able to attend follow-up. 7. Able to do labs at all study intervals (7 visits total) Exclusion Criteria: 1. Unable to provide a valid informed consent 2. Contraindications to cilostazol (namely (i) hypersensitivity, (ii) active pathologic bleeding, e.g. bleeding peptic ulcer, intracranial bleeding due to reversible platelet aggregation, (iii) congestive cardiac failure.) 3. Hemorrhagic stroke survivor within the last 2 years 4. Use of an anticoagulant medication or indication for use of an anticoagulant (e.g. atrial fibrillation) 5. On dual antiplatelet therapy (patients are eligible after completion of a course of dual antiplatelet therapy) 6. Modified Rankin Scale 5 7. Thrombocytopenia (platelet count \<1000,000) 8. Severe liver dysfunction (active hepatitis or hepatic insufficiency with Child-Pugh score B or C) 9. Congestive heart failure, defined as NYHA Class III or above (marked limitation of physical activity) 10. Nursing/pregnant mothers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for High-risk transient ischemic attack are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kwame Nkrumah University of Science & Technology

    Kumasi, Ghana

More trials for these conditions

Other studies related to the condition(s) this trial covers.